• Home
  • About
    • Our Constitution
    • Chairman’s words
    • Chairman and Board Members
  • Members
    • Become a Member
  • Annual Meetings
    • 1st Annual Meeting – 2010
    • 2nd Annual Meeting – 2011
    • 3rd Annual Meeting – 2012
    • 4th Annual Meeting -2013
    • 5th Annual Meeting- 2014
    • 7th Annual Meeting -2016
    • 8th Annual Meeting -2017
    • 9th Annual Meeting -2018
    • 10th Annual Meeting
    • 11th Annual Meeting
    • 12th Annual Meeting
  • Abstracts
    • Abstracts 2010
    • Abstracts 2011
    • Abstracts 2012
    • Abstracts 2014
    • Abstracts 2015
    • Abstracts 2016
    • Abstracts 2017
    • Abstracts 2018
    • Full Abstract List
  • Organizations
    • ISMFM
    • Israel Medical Association
    • Placenta – The Official Jourmal of IFPA
    • The Israel Fertility Association
    • SMFM
    • International Federation of Placenta Associations
    • The Endocrine Society of Australia
    • Nano Science
    • The Society for Reproductive Biology
    • Australasian Diabetes in Pregnancy Society
    • Society of Theriogenology
    • American College of Theriogenologists
    • The Fetal Medicine Foundation
  • Contact
Menu
  • Home
  • About
    • Our Constitution
    • Chairman’s words
    • Chairman and Board Members
  • Members
    • Become a Member
  • Annual Meetings
    • 1st Annual Meeting – 2010
    • 2nd Annual Meeting – 2011
    • 3rd Annual Meeting – 2012
    • 4th Annual Meeting -2013
    • 5th Annual Meeting- 2014
    • 7th Annual Meeting -2016
    • 8th Annual Meeting -2017
    • 9th Annual Meeting -2018
    • 10th Annual Meeting
    • 11th Annual Meeting
    • 12th Annual Meeting
  • Abstracts
    • Abstracts 2010
    • Abstracts 2011
    • Abstracts 2012
    • Abstracts 2014
    • Abstracts 2015
    • Abstracts 2016
    • Abstracts 2017
    • Abstracts 2018
    • Full Abstract List
  • Organizations
    • ISMFM
    • Israel Medical Association
    • Placenta – The Official Jourmal of IFPA
    • The Israel Fertility Association
    • SMFM
    • International Federation of Placenta Associations
    • The Endocrine Society of Australia
    • Nano Science
    • The Society for Reproductive Biology
    • Australasian Diabetes in Pregnancy Society
    • Society of Theriogenology
    • American College of Theriogenologists
    • The Fetal Medicine Foundation
  • Contact
Facebook
The Effects Of Pravastatin On The Human Placental Function: Lesson From The Ex-Vivo Model
Home ‹ 2015 Abstracts ‹ The Effects Of Pravastatin On The Human Placental Function: Lesson From The Ex-Vivo Model

Miss Adelina Balan1, Mrs. Shani S. Swissa1, Irit Szaingurten-Solodkin Ph.D.1, Valeria Feinshtein Ph.D.2, Mahmoud Huleihel Ph.D. 3, Gershon Holcberg M.D.4 and Ofer Beharier M.D. Ph.D.1,4

 

1Department of Physiology and Cell Biology, 2Department of Clinical Biochemistry and Pharmacology, 3The Shraga Segal Department of Microbiology and Immunology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel. 4Department of Obstetrics and Gynecology, Soroka University Medical Center and Ben-Gurion University of the Negev, Beer Sheva, Israel.

 

Introduction: Extensive research in animal models marked pravastatin as a treatment to eliminate preeclampsia. However, the effect of the drug on human tissue is extremely limited. Our study focuses on the secretion of angiogenic factors, inflammatory cytokines and nitric oxide (NO) in the human placenta following pravastatin exposure.

Methods: placental cotyledons were perfused in the absence (Cntl) or presence of pravastatin in the maternal reservoir (PraM) or the maternal and fetal reservoirs (PraMF). The concentrations of placental growth factor (PlGF), soluble Fms-like tyrosine kinase-1 (sFlt-1), soluble endoglin (sEng), tumor necrosis factor-a (TNF-a), interleukin (IL)-6 and IL-10 were measured by ELISA. Endothelial NO synthase (eNOS) expression in the placenta, was determined by immunoblot analysis. The concentrations of NO were determined by measurements of nitrite.

Results: PraM exposure did not alter PlGF, sFlt-1, sEng, TNF-a, IL-6 and IL-10 secretion, compared to Cntl. However, PraMF exposure significantly increased the secretion of sFlt-1 and IL-6 to the maternal circulation and IL-10 to the feral circulation. Both PraM and PraMF induced a significant increase in eNOS expression. Nevertheless, increased NO secretion to the maternal circulation was induced only in response to PraMF and the secretion to the fetal circulation, did not differ at all.

Conclusions: In the normal human placenta, maternal exposure to pravastatin does not change the secretion of angiogenic factors, inflammatory cytokines and NO. In contrast, maternal and fetal exposure to pravastatin initiates anti-angiogenic and pro-inflammatory reactions along with increased NO secretion.

« Previous
Next »
Powered by Netmii and Art + Web
All rights reserved to ISPR -Israel Society for Placental Research
Scroll to top